摘要
目的探讨新蝶呤在急性冠脉综合征患者的临床诊断中的价值。方法50例临床诊断冠心病患者,年龄53±11岁。每例患者均以冠脉造影技术从主动脉根部(AO)及冠状窦(CS)采血。采自CS与AO的血清新蝶呤以酶联免疫吸附法测定。结果UAP组及AMI组冠状窦与主动脉血清新蝶呤浓度差高于SAP组(P<0·05及P<0·01)。结论新蝶呤作为单核吞噬细胞激活的标志,对急性冠脉综合征的临床诊断有一定的应用价值。
Objective To analysis clinical value of neopterin by investigating plasma neopterin in patients with coronary heart disease. Methods Blood samples were obtained from the aortic root (AO) and coronary sinus (CS) of 50 patients, aging 53±11 years. Neopterin concentrations were measured by using an enzyme-linked immunosorbent assay method and the CSAO differences were calculated. Results Concentration of plasma neopterin in patients with UAP or AMI was higher than in patients with SAP (P〈0.05&P〈0.01). Conclusion The results indicate that neopterin is a useful marker of ACS in pa- tients with CAD, acting as an index of the activity of monocytes/macrophages.
出处
《福建医药杂志》
CAS
2007年第4期6-7,共2页
Fujian Medical Journal